ATE366804T1 - Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung - Google Patents
Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlungInfo
- Publication number
- ATE366804T1 ATE366804T1 AT99925265T AT99925265T ATE366804T1 AT E366804 T1 ATE366804 T1 AT E366804T1 AT 99925265 T AT99925265 T AT 99925265T AT 99925265 T AT99925265 T AT 99925265T AT E366804 T1 ATE366804 T1 AT E366804T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- pharmaceuticals
- manufacturing
- line
- formulae
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98MI001148A ITMI981148A1 (it) | 1998-05-22 | 1998-05-22 | Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366804T1 true ATE366804T1 (de) | 2007-08-15 |
Family
ID=11380089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99925265T ATE366804T1 (de) | 1998-05-22 | 1999-05-20 | Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7012062B2 (de) |
| EP (1) | EP1105467B9 (de) |
| JP (1) | JP2002516087A (de) |
| AT (1) | ATE366804T1 (de) |
| AU (1) | AU4163199A (de) |
| DE (1) | DE69936527T2 (de) |
| ES (1) | ES2292244T3 (de) |
| IT (1) | ITMI981148A1 (de) |
| PT (1) | PT1105467E (de) |
| WO (1) | WO1999061593A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI981148A1 (it) * | 1998-05-22 | 1999-11-22 | Therapicon Srl | Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie |
| JP2005047844A (ja) * | 2003-07-28 | 2005-02-24 | Hiroshi Yamazaki | 生物由来高分子物質の分解物、これを含む食品、化粧品、及び医薬品並びにそれらの製造方法 |
| ITMI20052327A1 (it) * | 2005-12-06 | 2007-06-07 | Therapicon Srl | Lisozima umano ricombinante modificato |
| EP2254591B1 (de) | 2008-02-08 | 2017-07-26 | Prothera, Inc. | Hemmung und behandlung von gastrointestinalen biofilmen |
| WO2011063394A2 (en) | 2009-11-23 | 2011-05-26 | Olmstead Stephen F | Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
| WO2014152678A1 (en) | 2013-03-15 | 2014-09-25 | University Of Massachusetts | Compositions and methods for delivering agents to the central nervous system |
| CN109528498B (zh) * | 2018-12-30 | 2021-05-18 | 美釉(西安)生物技术有限公司 | 一种用于深入封闭牙小管并防止生物膜形成的牙齿脱敏剂 |
| ES2980614T3 (es) * | 2019-07-19 | 2024-10-02 | Guangzhou Century Clinical Res Co Ltd | Composición farmacéutica que contiene lisozima y uso de la misma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| PL173978B1 (pl) * | 1992-07-13 | 1998-05-29 | Nika Health Products Ltd | Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| ATE214940T1 (de) | 1993-11-10 | 2002-04-15 | Enzon Inc | Verbesserte interferon-polymerkonjugate |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| ITMI981148A1 (it) * | 1998-05-22 | 1999-11-22 | Therapicon Srl | Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie |
-
1998
- 1998-05-22 IT IT98MI001148A patent/ITMI981148A1/it unknown
-
1999
- 1999-05-20 EP EP99925265A patent/EP1105467B9/de not_active Expired - Lifetime
- 1999-05-20 AT AT99925265T patent/ATE366804T1/de not_active IP Right Cessation
- 1999-05-20 WO PCT/IT1999/000142 patent/WO1999061593A1/en active IP Right Grant
- 1999-05-20 AU AU41631/99A patent/AU4163199A/en not_active Abandoned
- 1999-05-20 JP JP2000550978A patent/JP2002516087A/ja active Pending
- 1999-05-20 PT PT99925265T patent/PT1105467E/pt unknown
- 1999-05-20 ES ES99925265T patent/ES2292244T3/es not_active Expired - Lifetime
- 1999-05-20 DE DE69936527T patent/DE69936527T2/de not_active Expired - Fee Related
-
2002
- 2002-08-26 US US10/227,314 patent/US7012062B2/en not_active Expired - Fee Related
- 2002-08-26 US US10/227,313 patent/US7229809B2/en not_active Expired - Fee Related
-
2006
- 2006-10-02 US US11/537,882 patent/US20070086993A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7012062B2 (en) | 2006-03-14 |
| ITMI981148A1 (it) | 1999-11-22 |
| US20030124110A1 (en) | 2003-07-03 |
| EP1105467B1 (de) | 2007-07-11 |
| US20030129181A1 (en) | 2003-07-10 |
| US7229809B2 (en) | 2007-06-12 |
| US20070086993A1 (en) | 2007-04-19 |
| DE69936527D1 (de) | 2007-08-23 |
| WO1999061593A1 (en) | 1999-12-02 |
| PT1105467E (pt) | 2007-08-13 |
| JP2002516087A (ja) | 2002-06-04 |
| EP1105467B9 (de) | 2008-02-13 |
| DE69936527T2 (de) | 2008-03-13 |
| EP1105467A1 (de) | 2001-06-13 |
| ES2292244T3 (es) | 2008-03-01 |
| AU4163199A (en) | 1999-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE269312T1 (de) | N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren | |
| DE59803845D1 (de) | Sulfinsäurederivate und deren herstellung und verwendung | |
| MC2040A1 (fr) | Derives d'acides amines | |
| ES2151156T3 (es) | Derivados de acidos n-(aroil)glicina hidroxamicos y compuestos relacionados. | |
| MX9605128A (es) | Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
| MC2151A1 (fr) | Derives d'acides amines | |
| CA2215695A1 (en) | .beta.-sheet mimetics and use thereof as protease inhibitors | |
| MX9605974A (es) | Proceso mejorado en la sintesis de n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacet amida. | |
| ES2161955T3 (es) | Benzofuranil-ureas sustituidas con heterociclilcarbonilo. | |
| ATE366804T1 (de) | Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung | |
| MY115211A (en) | Novel amino acid derivatives, their preparation and use | |
| HUP0001164A2 (hu) | PF1022-ciklodepszipeptid-származékok | |
| ES2007177A6 (es) | Procedimiento para preparar amidas y tioamidas del acido 1'-desoxi-1'-(6-amino-9-purinil)-b-d-ribofuranuronico sustituidas en la posicion 2. | |
| TR200000907T2 (tr) | Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri. | |
| MC1985A1 (fr) | Derives d'acides amines | |
| CA2267945A1 (en) | Anticonvulsant derivatives useful in treating neuropathic pain | |
| MC2107A1 (fr) | Derives d'acides amines | |
| DK526087D0 (da) | Antikonvulsive aminosyrederivater | |
| AU683790B2 (en) | Nitric esters from derivatives of 2-(2-6-dihalophenylamino) phenylacetoxyacetic acid and their preparation process | |
| ATE317263T1 (de) | Diphosphonat derivate von therapeutisch wirksamen stoffen | |
| SG58291G (en) | Anticonvulsant agents | |
| BR9808047B1 (pt) | processo para a preparação de 2-nitroguanidinas 1,3-dissubstituìdas. | |
| TR200001122T2 (tr) | Farmasötikler olarak bifenil türevleri. | |
| ES2115543A1 (es) | Procedimiento para la obtencion de carbetocina y sus sales de adicion de acido farmaceuticamente aceptables o complejos de la misma. | |
| MC2109A1 (fr) | Dérivés d'acides aminés |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |